Table 1.
Clinical, biological, and pathological features of the MIBC patients included in this study.
| RHWU (N = 133) | TCGA (N = 247) | |
|---|---|---|
| Age (years) | 66 (26, 87) | 69 (37, 90) |
| Sex | ||
| female | 20 (15.04%) | 60 (24.29%) |
| male | 113 (84.96%) | 187 (75.71%) |
| pT stage | ||
| pT2 | 52 (39.10%) | 70 (28.34%) |
| pT3 | 63 (47.37%) | 131 (53.04%) |
| pT4 | 18 (13.53%) | 40 (16.19%) |
| pTx | 0 (0%) | 6 (2.43%) |
| pN stage | ||
| pN0 | 66 (49.62%) | 141 (57.09%) |
| pN1 | 34 (25.56%) | 29 (11.74%) |
| pN2 | 18 (13.53%) | 58 (23.48%) |
| pN3 | 15 (11.28%) | 5 (2.02%) |
| pNx | 0 (0%) | 14 (5.67%) |
| pM stage | ||
| pM0 | 129 (96.99%) | 100 (40.49%) |
| pM1 | 4 (3.01%) | 7 (2.83%) |
| pMx | 0 (0%) | 140 (56.68%) |
| pTNM stage | ||
| Stage II | 38 (28.57%) | 65 (16.31%) |
| Stage III | 74 (55.64%) | 86 (34.82%) |
| Stage IV | 21 (15.79%) | 96 (38.87%) |
| Lymphovascular invasion | ||
| No | 83 (62.41%) | 90 (33.21%) |
| Yes | 50 (37.59%) | 99 (36.53%) |
| Missing | 0 (0%) | 82 (30.26%) |
| Survival status | ||
| Alive | 77 (57.89%) | 121 (48.99%) |
| Dead | 56 (42.11%) | 126 (51.01%) |
| OS time (months) | 15.3 (1.9, 66.0) | 17.5 (0.5, 114.0) |
MIBC, Muscle-invasive Bladder Cancer; RHWU, Renmin Hospital of Wuhan University; TCGA, The Cancer Genome Atlas.